Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
نویسندگان
چکیده
منابع مشابه
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
This review discusses two distinct, yet related, mechanisms of sodium-glucose cotransporter 2 (SGLT2) inhibition: Calorie restriction mimicry (CRM) and pro-ketogenic effect, which may explain their cardiovascular benefits. We term these adaptive CRM and pro-ketogenic effects of SGLT2 inhibition, the Robin Hood hypothesis. In English history, Robin Hood was a "good person," who stole from the ri...
متن کاملSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
UNLABELLED Blood glucose-lowering treatment options generally target insulin action or beta-cell function. In diabetes, expression of the sodium-glucose cotransporter-2 (SGLT2) genes is up-regulated and renal threshold increased, resulting in increased glucose reabsorption from glomerular filtrate, reducing urinary glucose excretion and worsening the hyperglycemic condition. The SGLT2 inhibitor...
متن کاملEnergy Balance After Sodium–Glucose Cotransporter 2 Inhibition
OBJECTIVE Sodium-glucose cotransporter 2 (SGLT2) inhibitors cause substantially less weight loss than expected from the energy excreted via glycosuria. Our aim was to analyze this phenomenon quantitatively. RESEARCH DESIGN AND METHODS Eighty-six patients with type 2 diabetes (HbA1c 7.8 ± 0.8% [62 ± 9 mmol/mol], estimated glomerular filtration rate [eGFR] 89 ± 19 mL ⋅ min(-1) ⋅ 1.73 m(-2)) rec...
متن کاملEnergy Balance After Sodium Glucose Cotransporter 2 (SGLT2) Inhibition
Eighty-six patients with type 2 diabetes (HbA1c = 7.86 0.8% [62 6 9 mmol/mol], estimated glomerular filtration rate [eGFR] = 89 6 19 mL · min · 1.73 m) received empagliflozin (25 mg/day) for 90 weeks with frequent (n = 11) assessments of body weight, eGFR, and fasting plasma glucose (FPG). Time-dependent glucose filtration was calculated as the product of eGFR and FPG; time-dependent glycosuria...
متن کاملThe effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease. In this analysis, we explored the hypothesis that empagliflozin may have an impact on urinary peptides associated with chronic kidney disease (CKD). In this post-hoc, exploratory analysis, we investigated urine samples obtained from 40 patie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Endocrinology and Metabolism
سال: 2016
ISSN: 2230-8210
DOI: 10.4103/2230-8210.183826